{"DataElement":{"publicId":"12988910","version":"1","preferredName":"Study Pediatric Treatment Arm Identifier","preferredDefinition":"A sequence of characters used to identify, name, or characterize the specific treatment plan within a clinical trial that describes the activities a pediatric subject will be involved in as he or she progresses through the study.","longName":"12988907v1.00:12988909v1.00","context":"Pediatric Cancer","contextVersion":"1","DataElementConcept":{"publicId":"12988907","version":"1","preferredName":"Study Pediatric Treatment Arm","preferredDefinition":"A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:Having to do with children._A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","longName":"2619600v1.00:12988906v1.00","context":"Pediatric Cancer","contextVersion":"1","ObjectClass":{"publicId":"2619600","version":"1","preferredName":"Study","preferredDefinition":"A detailed critical inspection; a research project.","longName":"C63536","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Study","conceptCode":"C63536","definition":"A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CBEE308-E532-03A0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-28","endDate":null,"createdBy":"UMLLOADER_CAELMIR","dateCreated":"2007-03-28","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"12988906","version":"1","preferredName":"Pediatric Protocol Treatment Arm","preferredDefinition":"Having to do with children._A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","longName":"C39299:C15538","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pediatric","conceptCode":"C39299","definition":"Having to do with children.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F645240B-F6C4-3667-E053-731AD00A80B4","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-03-06","modifiedBy":"COLBERTM","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F645240B-F6C5-3667-E053-731AD00A80B4","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-03-06","modifiedBy":"JKNABLE","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":"1/5/24 removed \"protocol\" from LN for consistency with CCDI variable. jk; 10/27/23 Changed Origin from CRDC to PCDC. mr;  3/6/23 Created per PCDC metadata template. mr","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12988909","version":"1","preferredName":"Protocol Treatment Arm Identifier","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"12988909v1.00","context":"Pediatric Cancer","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"MAP-GR","valueDescription":null,"ValueMeaning":{"publicId":"13006733","version":"1","preferredName":"MAP-GR","longName":"13006733v1.00","preferredDefinition":"A control arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) after good response to the MAP regimen pre-operatively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MAP-GR","conceptCode":"C186769","definition":"A control arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) after good response to the MAP regimen pre-operatively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F662AF4F-7845-319D-E053-731AD00A17F3","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F662AF4F-7846-319D-E053-731AD00A17F3","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"MAP-IFN-GR","valueDescription":null,"ValueMeaning":{"publicId":"13006734","version":"1","preferredName":"MAP-IFN-GR","longName":"13006734v1.00","preferredDefinition":"An experimental treatment arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) plus interferon (IFN) post-operatively after good response to the MAP regimen pre-operatively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MAP-IFN-GR","conceptCode":"C186770","definition":"An experimental treatment arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) plus interferon (IFN) post-operatively after good response to the MAP regimen pre-operatively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6633482-6CD8-4308-E053-731AD00AADA0","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6633482-6CD9-4308-E053-731AD00AADA0","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"MAP-PR","valueDescription":null,"ValueMeaning":{"publicId":"13006735","version":"1","preferredName":"MAP-PR","longName":"13006735v1.00","preferredDefinition":"A control arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) after poor response to the MAP regimen pre-operatively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MAP-PR","conceptCode":"C186771","definition":"A control arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) after poor response to the MAP regimen pre-operatively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6633BED-30C6-43C3-E053-731AD00A34D2","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6633BED-30C7-43C3-E053-731AD00A34D2","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"MAP-IE-PR","valueDescription":null,"ValueMeaning":{"publicId":"13006736","version":"1","preferredName":"MAP-IE-PR","longName":"13006736v1.00","preferredDefinition":"An experimental treatment arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) plus a regimen of ifosfamide and etoposide (IE) post-operatively after poor response to the MAP regimen pre-operatively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MAP-IE-PR","conceptCode":"C186772","definition":"An experimental treatment arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) plus a regimen of ifosfamide and etoposide (IE) post-operatively after poor response to the MAP regimen pre-operatively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F663498F-76C2-48CD-E053-731AD00AE794","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663498F-76C4-48CD-E053-731AD00AE794","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"MAP-NR","valueDescription":null,"ValueMeaning":{"publicId":"13006737","version":"1","preferredName":"MAP-NR","longName":"13006737v1.00","preferredDefinition":"A control arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) with no response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MAP-NR","conceptCode":"C186773","definition":"A control arm for patients receiving a regimen of methotrexate, doxorubicin and cisplatin (MAP) with no response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F663498F-76C3-48CD-E053-731AD00AE794","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663498F-76C5-48CD-E053-731AD00AE794","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"MAP","valueDescription":null,"ValueMeaning":{"publicId":"6161739","version":"1","preferredName":"Cisplatin-Doxorubicin-Methotrexate Regimen","longName":"6161739","preferredDefinition":"A regimen consisting of cisplatin, doxorubicin, and methotrexate used as an adjuvant treatment for localized childhood osteosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MAP Regimen","conceptCode":"C67339","definition":"A regimen consisting of cisplatin, doxorubicin, and methotrexate that can be used in the treatment of osteosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F533A-F89B-5967-E053-F662850A365F","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-05","modifiedBy":"COOPERM","dateModified":"2018-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663498F-76C6-48CD-E053-731AD00AE794","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"POSTOP-CHEMO","valueDescription":null,"ValueMeaning":{"publicId":"13006738","version":"1","preferredName":"POSTOP-CHEMO","longName":"13006738v1.00","preferredDefinition":"A treatment arm for patients receiving postoperative chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"POSTOP-CHEMO","conceptCode":"C186775","definition":"A treatment arm for patients receiving postoperative chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6635315-B26E-49F4-E053-731AD00A160B","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6635315-B26F-49F4-E053-731AD00A160B","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"CHEMO-ZOL","valueDescription":null,"ValueMeaning":{"publicId":"13006741","version":"1","preferredName":"CHEMO-ZOL","longName":"13006741v1.00","preferredDefinition":"A treatment arm for patients receiving chemotherapy in combination with zoledronic acid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHEMO-ZOL","conceptCode":"C186777","definition":"A treatment arm for patients receiving chemotherapy in combination with zoledronic acid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F663F133-CE4A-68AB-E053-731AD00A4519","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663F133-CE4E-68AB-E053-731AD00A4519","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"CHEMO","valueDescription":null,"ValueMeaning":{"publicId":"5102333","version":"1","preferredName":"Chemotherapy","longName":"5102333","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-0232-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663F133-CE4F-68AB-E053-731AD00A4519","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"REG-ACTIVE","valueDescription":null,"ValueMeaning":{"publicId":"13006742","version":"1","preferredName":"REG-ACTIVE","longName":"13006742v1.00","preferredDefinition":"An experimental treatment arm for patients receiving regorafenib as the active drug.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"REG-ACTIVE","conceptCode":"C186778","definition":"An experimental treatment arm for patients receiving regorafenib as the active drug.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F663F133-CE4B-68AB-E053-731AD00A4519","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663F133-CE50-68AB-E053-731AD00A4519","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"REG-PLACEBO","valueDescription":null,"ValueMeaning":{"publicId":"13006743","version":"1","preferredName":"REG-PLACEBO","longName":"13006743v1.00","preferredDefinition":"A control arm for patients receiving placebo instead of the experimental drug regorafenib.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"REG-PLACEBO","conceptCode":"C186779","definition":"A control arm for patients receiving placebo instead of the experimental drug regorafenib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F663F133-CE4C-68AB-E053-731AD00A4519","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663F133-CE51-68AB-E053-731AD00A4519","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"DOX","valueDescription":null,"ValueMeaning":{"publicId":"5567088","version":"1","preferredName":"Doxorubicin Hydrochloride","longName":"5567088","preferredDefinition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin Hydrochloride","conceptCode":"C1326","definition":"The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40CFD039-BC52-556D-E053-F662850AED1E","latestVersionIndicator":"Yes","beginDate":"2016-11-08","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663F133-CE52-68AB-E053-731AD00A4519","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"POSTOP-CHEMO-MIF","valueDescription":null,"ValueMeaning":{"publicId":"13006744","version":"1","preferredName":"POSTOP-CHEMO-MIF","longName":"13006744v1.00","preferredDefinition":"A treatment arm for patients receiving mifepristone as part of the postoperative chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"POSTOP-CHEMO-MIF","conceptCode":"C186776","definition":"A treatment arm for patients receiving mifepristone as part of the postoperative chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F663F133-CE4D-68AB-E053-731AD00A4519","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F663F133-CE53-68AB-E053-731AD00A4519","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"DOX-IFOS","valueDescription":null,"ValueMeaning":{"publicId":"13007135","version":"1","preferredName":"AI Regimen","longName":"13007135v1.00","preferredDefinition":"A regimen consisting of doxorubicin and ifosfamide used for the treatment of unresectable soft tissue sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AI Regimen","conceptCode":"C63686","definition":"A regimen consisting of doxorubicin and ifosfamide used for the treatment of unresectable soft tissue sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65E4-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65EE-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS0031:3W-VDC-MESNA+IFO-GCSF","valueDescription":null,"ValueMeaning":{"publicId":"13007136","version":"1","preferredName":"3W-VDC-MESNA+IFO-GCSF Treatment Arm of AEWS0031","longName":"13007136v1.00","preferredDefinition":"The treatment arm 3W-VDC-MESNA+IFO-GCSF of EWS study AEWS0031.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"3W-VDC-MESNA+IFO-GCSF Treatment Arm of AEWS0031","conceptCode":"C174975","definition":"The treatment arm 3W-VDC-MESNA+IFO-GCSF of EWS study AEWS0031.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65E5-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65EF-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS0031:2W-VDC-MESNA+IFO-GCSF","valueDescription":null,"ValueMeaning":{"publicId":"13007137","version":"1","preferredName":"2W-VDC-MESNA+IFO-GCSF Treatment Arm of AEWS0031","longName":"13007137v1.00","preferredDefinition":"The treatment arm 2W-VDC-MESNA+IFO-GCSF of EWS study AEWS0031.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"2W-VDC-MESNA+IFO-GCSF Treatment Arm of AEWS0031","conceptCode":"C174976","definition":"The treatment arm 2W-VDC-MESNA+IFO-GCSF of EWS study AEWS0031.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65E6-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65F0-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS1221:VDC/IE","valueDescription":null,"ValueMeaning":{"publicId":"13007138","version":"1","preferredName":"VDC/IE Treatment Arm of AEWS1221","longName":"13007138v1.00","preferredDefinition":"The treatment arm VDC/IE of EWS study AEWS1221.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VDC/IE Treatment Arm of AEWS1221","conceptCode":"C174977","definition":"The treatment arm VDC/IE of EWS study AEWS1221.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65E7-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65F1-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS0331:VIDE-Surgery-R1-VAI-VAC/VAI","valueDescription":null,"ValueMeaning":{"publicId":"13007140","version":"1","preferredName":"VIDE-Surgery-R1-VAI-VAC/VAI Treatment Arm of AEWS0331","longName":"13007140v1.00","preferredDefinition":"The treatment arm VIDE-Surgery-R1-VAI-VAC/VAI of EWS study AEWS0331.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIDE-Surgery-R1-VAI-VAC/VAI Treatment Arm of AEWS0331","conceptCode":"C174979","definition":"The treatment arm VIDE-Surgery-R1-VAI-VAC/VAI of EWS study AEWS0331.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65E9-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65F2-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS0331:VIDE-Surgery-R2-VAI-VAI/BuMel","valueDescription":null,"ValueMeaning":{"publicId":"13007141","version":"1","preferredName":"VIDE-Surgery-R2-VAI-VAI/BuMel Treatment Arm of AEWS0331","longName":"13007141v1.00","preferredDefinition":"The treatment arm VIDE-Surgery-R2-VAI-VAI/BuMel of EWS study AEWS0331.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIDE-Surgery-R2-VAI-VAI/BuMel Treatment Arm of AEWS0331","conceptCode":"C174980","definition":"The treatment arm VIDE-Surgery-R2-VAI-VAI/BuMel of EWS study AEWS0331.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65EA-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65F3-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS0331:VIDE-Surgery-R3-VAI-MEME/TreoMel/BuMel/P2","valueDescription":null,"ValueMeaning":{"publicId":"13007142","version":"1","preferredName":"VIDE-Surgery-R3-VAI-MEME/TreoMel/BuMel/P2 Treatment Arm of AEWS0331","longName":"13007142v1.00","preferredDefinition":"The treatment arm VIDE-Surgery-R3-VAI-MEME/TreoMel/BuMel/P2 of EWS study AEWS0331.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIDE-Surgery-R3-VAI-MEME/TreoMel/BuMel/P2 Treatment Arm of AEWS0331","conceptCode":"C174981","definition":"The treatment arm VIDE-Surgery-R3-VAI-MEME/TreoMel/BuMel/P2 of EWS study AEWS0331.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65EB-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65F4-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS1031:VIDEC","valueDescription":null,"ValueMeaning":{"publicId":"13007143","version":"1","preferredName":"VIDEC Treatment Arm of AEWS1031","longName":"13007143v1.00","preferredDefinition":"The treatment arm VIDEC of EWS study AEWS1031.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIDEC Treatment Arm of AEWS1031","conceptCode":"C174982","definition":"The treatment arm VIDEC of EWS study AEWS1031.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65EC-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65F5-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS1031:VIDEC+Topotecan","valueDescription":null,"ValueMeaning":{"publicId":"13007144","version":"1","preferredName":"VIDEC+Topotecan Treatment Arm of AEWS1031","longName":"13007144v1.00","preferredDefinition":"The treatment arm VIDEC+Topotecan of EWS study AEWS1031.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIDEC+Topotecan Treatment Arm of AEWS1031","conceptCode":"C174983","definition":"The treatment arm VIDEC+Topotecan of EWS study AEWS1031.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65ED-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65F6-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS1221:VDC/IE+Ganitumab","valueDescription":null,"ValueMeaning":{"publicId":"13007139","version":"1","preferredName":"VDC/IE+Ganitumab Treatment Arm of AEWS1221","longName":"13007139v1.00","preferredDefinition":"The treatment arm VDC/IE+Ganitumab of EWS study AEWS1221.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VDC/IE+Ganitumab Treatment Arm of AEWS1221","conceptCode":"C174978","definition":"The treatment arm VDC/IE+Ganitumab of EWS study AEWS1221.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65E8-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65F7-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"EICESS92:SR/VAIA","valueDescription":null,"ValueMeaning":{"publicId":"13007145","version":"1","preferredName":"SR/VAIA Treatment Arm of EICESS92","longName":"13007145v1.00","preferredDefinition":"The treatment arm SR/VAIA of EWS study EICESS92.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SR/VAIA Treatment Arm of EICESS92","conceptCode":"C174984","definition":"The treatment arm SR/VAIA of EWS study EICESS92.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65F8-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-65FF-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"EICESS92:SR/VACA","valueDescription":null,"ValueMeaning":{"publicId":"13007146","version":"1","preferredName":"SR/VACA Treatment Arm of EICESS92","longName":"13007146v1.00","preferredDefinition":"The treatment arm SR/VACA of EWS study EICESS92.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SR/VACA Treatment Arm of EICESS92","conceptCode":"C174985","definition":"The treatment arm SR/VACA of EWS study EICESS92.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65F9-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-6600-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"EICESS92:HR/EVAIA","valueDescription":null,"ValueMeaning":{"publicId":"13007148","version":"1","preferredName":"HR/EVAIA Treatment Arm of EICESS92","longName":"13007148v1.00","preferredDefinition":"The treatment arm HR/EVAIA of EWS study EICESS92.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HR/EVAIA Treatment Arm of EICESS92","conceptCode":"C174987","definition":"The treatment arm HR/EVAIA of EWS study EICESS92.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65FB-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-6601-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS07P1:VAIA-VACA","valueDescription":null,"ValueMeaning":{"publicId":"13007149","version":"1","preferredName":"VAIA-VACA Treatment Arm of AEWS07P1","longName":"13007149v1.00","preferredDefinition":"The treatment arm VAIA-VACA of EWS study AEWS07P1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAIA-VACA Treatment Arm of AEWS07P1","conceptCode":"C174988","definition":"The treatment arm VAIA-VACA of EWS study AEWS07P1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65FC-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-6602-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS07P1:VAIA-VAIA","valueDescription":null,"ValueMeaning":{"publicId":"13007150","version":"1","preferredName":"VAIA-VAIA Treatment Arm of AEWS07P1","longName":"13007150v1.00","preferredDefinition":"The treatment arm VAIA-VAIA of EWS study AEWS07P1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAIA-VAIA Treatment Arm of AEWS07P1","conceptCode":"C174989","definition":"The treatment arm VAIA-VAIA of EWS study AEWS07P1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65FD-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-6603-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"AEWS07P1:EVAIA-EVAIA","valueDescription":null,"ValueMeaning":{"publicId":"13007151","version":"1","preferredName":"EVAIA-EVAIA Treatment Arm of AEWS07P1","longName":"13007151v1.00","preferredDefinition":"The treatment arm EVAIA-EVAIA of EWS study AEWS07P1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EVAIA-EVAIA Treatment Arm of AEWS07P1","conceptCode":"C174990","definition":"The treatment arm EVAIA-EVAIA of EWS study AEWS07P1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65FE-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-6604-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"EICESS92:HR/VAIA","valueDescription":null,"ValueMeaning":{"publicId":"13007147","version":"1","preferredName":"HR/VAIA Treatment Arm of EICESS92","longName":"13007147v1.00","preferredDefinition":"The treatment arm HR/VAIA of EWS study EICESS92.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HR/VAIA Treatment Arm of EICESS92","conceptCode":"C174986","definition":"The treatment arm HR/VAIA of EWS study EICESS92.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F66463EF-65FA-7B5D-E053-731AD00AEBB7","latestVersionIndicator":"Yes","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F66463EF-6605-7B5D-E053-731AD00AEBB7","beginDate":"2023-03-08","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-03-08","modifiedBy":"SOKKERL","dateModified":"2023-03-08","deletedIndicator":"No"},{"value":"JACLS AML99:HR","valueDescription":null,"ValueMeaning":{"publicId":"14666510","version":"1","preferredName":"JACLSAML99 AML Study Identifier High Risk","longName":"14666510v1.00","preferredDefinition":"The identifier JACLSAML99, assigned to a study in an AML clinical trial._The potential future harm that may arise from some present action or attribute or condition is almost certain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"JACLSAML99 AML Study Identifier","conceptCode":"C168943","definition":"The identifier JACLSAML99, assigned to a study in an AML clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"High Risk","conceptCode":"C102401","definition":"The potential future harm that may arise from some present action or attribute or condition is almost certain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CF59A51-DD9D-7CE3-E063-731AD00ACA50","latestVersionIndicator":"Yes","beginDate":"2023-12-20","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-12-20","modifiedBy":"COLBERTM","dateModified":"2023-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CF59A51-DDA0-7CE3-E063-731AD00ACA50","beginDate":"2023-12-20","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-12-20","modifiedBy":"COLBERTM","dateModified":"2023-12-20","deletedIndicator":"No"},{"value":"JACLS AML99:IR","valueDescription":null,"ValueMeaning":{"publicId":"14666511","version":"1","preferredName":"JACLSAML99 AML Study Identifier Intermediate Risk","longName":"14666511v1.00","preferredDefinition":"The identifier JACLSAML99, assigned to a study in an AML clinical trial._The potential future harm that may arise from some present action or attribute or condition is moderate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"JACLSAML99 AML Study Identifier","conceptCode":"C168943","definition":"The identifier JACLSAML99, assigned to a study in an AML clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intermediate Risk","conceptCode":"C102402","definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CF59A51-DD9E-7CE3-E063-731AD00ACA50","latestVersionIndicator":"Yes","beginDate":"2023-12-20","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-12-20","modifiedBy":"COLBERTM","dateModified":"2023-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CF59A51-DDA1-7CE3-E063-731AD00ACA50","beginDate":"2023-12-20","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-12-20","modifiedBy":"COLBERTM","dateModified":"2023-12-20","deletedIndicator":"No"},{"value":"JACLS AML99:LR","valueDescription":null,"ValueMeaning":{"publicId":"14666512","version":"1","preferredName":"JACLSAML99 AML Study Identifier Low Risk","longName":"14666512v1.00","preferredDefinition":"The identifier JACLSAML99, assigned to a study in an AML clinical trial._The potential future harm that may arise from some present action or attribute or condition is small.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"JACLSAML99 AML Study Identifier","conceptCode":"C168943","definition":"The identifier JACLSAML99, assigned to a study in an AML clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Low Risk","conceptCode":"C102403","definition":"The potential future harm that may arise from some present action or attribute or condition is small.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CF59A51-DD9F-7CE3-E063-731AD00ACA50","latestVersionIndicator":"Yes","beginDate":"2023-12-20","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-12-20","modifiedBy":"COLBERTM","dateModified":"2023-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CF59A51-DDA2-7CE3-E063-731AD00ACA50","beginDate":"2023-12-20","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-12-20","modifiedBy":"COLBERTM","dateModified":"2023-12-20","deletedIndicator":"No"},{"value":"ACNS0331 Arm I Includes 3-7 Years of Age, LDCSI, IFRT","valueDescription":null,"ValueMeaning":{"publicId":"14679001","version":"1","preferredName":"ACNS0331 Arm I Includes 3-7 Years of Age, LDCSI, IFRT","longName":"14679001v1.00","preferredDefinition":"Patients 3-7 years of age randomized with the following course sequence: 1) Lowered dose craniospinal irradiation (LDCSI), 2) Involved-field radiation therapy (IFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0331 Arm I Includes 3-7 Years of Age, LDCSI, IFRT","conceptCode":"C203562","definition":"Patients 3-7 years of age randomized with the following course sequence: 1) Lowered dose craniospinal irradiation (LDCSI), 2) Involved-field radiation therapy (IFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F10FCBE-C987-51E2-E063-731AD00A6648","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F10FCBE-C988-51E2-E063-731AD00A6648","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0331 Arm II Includes 3-7 Years of Age, LDCSI, PFRT","valueDescription":null,"ValueMeaning":{"publicId":"14679002","version":"1","preferredName":"ACNS0331 Arm II Includes 3-7 Years of Age, LDCSI, PFRT","longName":"14679002v1.00","preferredDefinition":"Patients 3-7 years of age randomized with the following course sequence: 1) Lowered dose craniospinal irradiation (LDCSI), 2) Whole posterior fossa radiation therapy (PFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0331 Arm II Includes 3-7 Years of Age, LDCSI, PFRT","conceptCode":"C203563","definition":"Patients 3-7 years of age randomized with the following course sequence: 1) Lowered dose craniospinal irradiation (LDCSI), 2) Whole posterior fossa radiation therapy (PFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76C2-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76D6-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0331 Arm III Includes 3-7 Years of Age, SDCSI, IFRT","valueDescription":null,"ValueMeaning":{"publicId":"14679003","version":"1","preferredName":"ACNS0331 Arm III Includes 3-7 Years of Age, SDCSI, IFRT","longName":"14679003v1.00","preferredDefinition":"Patients 3-7 years of age randomized with the following course sequence: 1) Standard dose craniospinal irradiation (SDCSI) 2) Involved-field radiation therapy (IFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0331 Arm III Includes 3-7 Years of Age, SDCSI, IFRT","conceptCode":"C203564","definition":"Patients 3-7 years of age randomized with the following course sequence: 1) Standard dose craniospinal irradiation (SDCSI) 2) Involved-field radiation therapy (IFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76C3-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76D7-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0331 Arm IV Includes 3-7 Years of Age, SDCSI, PFRT","valueDescription":null,"ValueMeaning":{"publicId":"14679004","version":"1","preferredName":"ACNS0331 Arm IV Includes 3-7 Years of Age, SDCSI, PFRT","longName":"14679004v1.00","preferredDefinition":"Patients 3-7 years of age randomized with the following course sequence: 1) Standard dose craniospinal irradiation (SDCSI) 2) Whole posterior fossa radiation therapy (PFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0331 Arm IV Includes 3-7 Years of Age, SDCSI, PFRT","conceptCode":"C203565","definition":"Patients 3-7 years of age randomized with the following course sequence: 1) Standard dose craniospinal irradiation (SDCSI) 2) Whole posterior fossa radiation therapy (PFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76C4-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76D8-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0331 Arm V Includes 8-21 Years of Age, SDCSI, IFRT","valueDescription":null,"ValueMeaning":{"publicId":"14679005","version":"1","preferredName":"ACNS0331 Arm V Includes 8-21 Years of Age, SDCSI, IFRT","longName":"14679005v1.00","preferredDefinition":"Patients 8-21 years of age randomized with the following course sequence: 1) Standard dose craniospinal irradiation (SDCSI) 2) Involved-field radiation therapy (IFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0331 Arm V Includes 8-21 Years of Age, SDCSI, IFRT","conceptCode":"C203566","definition":"Patients 8-21 years of age randomized with the following course sequence: 1) Standard dose craniospinal irradiation (SDCSI) 2) Involved-field radiation therapy (IFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76C5-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76D9-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0331 Arm VI Includes 8-21 Years of Age, SDCSI, PFRT","valueDescription":null,"ValueMeaning":{"publicId":"14679006","version":"1","preferredName":"ACNS0331 Arm VI Includes 8-21 Years of Age, SDCSI, PFRT","longName":"14679006v1.00","preferredDefinition":"Patients 8-21 years of age randomized with the following course sequence: 1) Standard dose craniospinal irradiation (SDCSI) 2) Whole posterior fossa radiation therapy (PFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0331 Arm VI Includes 8-21 Years of Age, SDCSI, PFRT","conceptCode":"C203567","definition":"Patients 8-21 years of age randomized with the following course sequence: 1) Standard dose craniospinal irradiation (SDCSI) 2) Whole posterior fossa radiation therapy (PFRT) boost. (Michalski JM, et al.  J Clin Oncol. 2021 Aug 20;39(24):2685-2697.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76C6-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76DA-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0332 Arm A","valueDescription":null,"ValueMeaning":{"publicId":"14679007","version":"1","preferredName":"ACNS0332 Arm A","longName":"14679007v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Chemoradiotherapy: Patients undergo radiation therapy once daily (QD) five days a week for 6 weeks. Patients also receive vincristine sulfate intravenously (IV) over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy, 2) Maintenance Therapy: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim subcutaneously (SC) or IV beginning on day 4 and continuing until blood counts recover (at least 10 days). Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. (Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0332 Arm A","conceptCode":"C203568","definition":"Patients randomized with the following course sequence: 1) Chemoradiotherapy: Patients undergo radiation therapy once daily (QD) five days a week for 6 weeks. Patients also receive vincristine sulfate intravenously (IV) over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy, 2) Maintenance Therapy: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim subcutaneously (SC) or IV beginning on day 4 and continuing until blood counts recover (at least 10 days). Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. (Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76C7-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76DB-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0332 Arm B Includes Carboplatin","valueDescription":null,"ValueMeaning":{"publicId":"14679008","version":"1","preferredName":"ACNS0332 Arm B Includes Carboplatin","longName":"14679008v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Chemoradiotherapy: Patients receive vincristine sulfate and undergo radiation therapy as in Arm I. Patients also receive carboplatin IV over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy, 2) Maintenance Therapy: Patients receive maintenance therapy as in Arm I. (Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0332 Arm B Includes Carboplatin","conceptCode":"C203569","definition":"Patients randomized with the following course sequence: 1) Chemoradiotherapy: Patients receive vincristine sulfate and undergo radiation therapy as in Arm I. Patients also receive carboplatin intravenously (IV) over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy, 2) Maintenance Therapy: Patients receive maintenance therapy as in Arm I. (Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76C8-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76DC-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0332 Arm C Includes Isotretinoin","valueDescription":null,"ValueMeaning":{"publicId":"14679009","version":"1","preferredName":"ACNS0332 Arm C Includes Isotretinoin","longName":"14679009v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Chemoradiotherapy: Patients undergo chemoradiotherapy as in Arm I. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy, 2) Maintenance Therapy: Patients receive isotretinoin orally (PO) twice daily (BID) on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm I maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy, 3) Continuation Therapy: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0332 Arm C Includes Isotretinoin","conceptCode":"C203570","definition":"Patients randomized with the following course sequence: 1) Chemoradiotherapy: Patients undergo chemoradiotherapy as in Arm I. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy, 2) Maintenance Therapy: Patients receive isotretinoin orally (PO) twice daily (BID) on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm I maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy, 3) Continuation Therapy: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76C9-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76DD-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0332 Arm D Includes Carboplatin and Isotretinoin","valueDescription":null,"ValueMeaning":{"publicId":"14679010","version":"1","preferredName":"ACNS0332 Arm D Includes Carboplatin and Isotretinoin","longName":"14679010v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Chemoradiotherapy: Patients undergo chemoradiotherapy as in Arm II. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy, 2) Maintenance Therapy: Patients receive maintenance therapy as in Arm III. Patients then proceed to continuation therapy, 3) Continuation Therapy: Patients receive continuation therapy as in Arm III. (Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0332 Arm D Includes Carboplatin and Isotretinoin","conceptCode":"C203571","definition":"Patients randomized with the following course sequence: 1) Chemoradiotherapy: Patients undergo chemoradiotherapy as in Arm II. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy, 2) Maintenance Therapy: Patients receive maintenance therapy as in Arm III. Patients then proceed to continuation therapy, 3) Continuation Therapy: Patients receive continuation therapy as in Arm III. (Leary SES, et al. JAMA Oncol. 2021 Sep 1;7(9):1313-1321.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76CA-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76DE-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0333 Arm I Includes Chemotherapy, Autologous PBSC, 3D-CRT","valueDescription":null,"ValueMeaning":{"publicId":"14679011","version":"1","preferredName":"ACNS0333 Arm I Includes Chemotherapy, Autologous PBSC, 3D-CRT","longName":"14679011v1.00","preferredDefinition":"Patients received treatment in the following courses sequence: 1) Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers (Chemotherapy), 2) Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous peripheral blood stem cells (PBSC) rescue on approximately day 4, 3) After consolidation therapy, patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks. (Reddy AT, et al. J Clin Oncol. 2020 Oct 1;38(28):3353-3354.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0333 Arm I Includes Chemotherapy, Autologous PBSC, 3D-CRT","conceptCode":"C203572","definition":"Patients received treatment in the following courses sequence: 1) Patients receive vincristine intravenously (IV) on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers (Chemotherapy), 2) Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous peripheral blood stem cells (PBSC) rescue on approximately day 4, 3) After consolidation therapy, patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks. (Reddy AT, et al. J Clin Oncol. 2020 Oct 1;38(28):3353-3354.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76CB-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76DF-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0333 Arm II Includes Chemotherapy, 3D-CRT, Autologous PBSC","valueDescription":null,"ValueMeaning":{"publicId":"14679012","version":"1","preferredName":"ACNS0333 Arm II Includes Chemotherapy, 3D-CRT, Autologous PBSC","longName":"14679012v1.00","preferredDefinition":"Patients received treatment in the following courses sequence: 1) Chemotherapy: Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers, 2) Patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks, 3) Within 2-6 weeks after completion of radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous peripheral blood stem cells (PBSC) rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. (Reddy AT, et al. J Clin Oncol. 2020 Oct 1;38(28):3353-3354.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0333 Arm II Includes Chemotherapy, 3D-CRT, Autologous PBSC","conceptCode":"C203573","definition":"Patients received treatment in the following courses sequence: 1) Chemotherapy: Patients receive vincristine intravenously (IV) on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers, 2) Patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks, 3) Within 2-6 weeks after completion of radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous peripheral blood stem cells (PBSC) rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. (Reddy AT, et al. J Clin Oncol. 2020 Oct 1;38(28):3353-3354.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76CC-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E0-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0334 Arm A Includes Induction Plus Consolidation Chemotherapy, Autologous PBSC","valueDescription":null,"ValueMeaning":{"publicId":"14679013","version":"1","preferredName":"ACNS0334 Arm A Includes Induction Plus Consolidation Chemotherapy, Autologous PBSC","longName":"14679013v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Induction: Patients receive vincristine sulfate IV on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses, 2) Consolidation Chemotherapy: Patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. 3) Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. (Lafay-Cousin L, et al. Cancers (Basel). 2022 Feb 7;14(3):837.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0334 Arm A Includes Induction Plus Consolidation Chemotherapy, Autologous PBSC","conceptCode":"C203574","definition":"Patients randomized with the following course sequence: 1) Induction: Patients receive vincristine sulfate intravenously (IV) on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses, 2) Consolidation Chemotherapy: Patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. 3) Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. (Lafay-Cousin L, et al. Cancers (Basel). 2022 Feb 7;14(3):837.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76CD-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E1-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"ACNS0334 Arm B Includes Induction Plus Consolidation Chemotherapy, Autologous PBSC","valueDescription":null,"ValueMeaning":{"publicId":"14679014","version":"1","preferredName":"ACNS0334 Arm B Includes Induction Plus Consolidation Chemotherapy, Autologous PBSC","longName":"14679014v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Induction: Patients receive vincristine sulfate IV on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or orally every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses, 2) Consolidation Chemotherapy: Patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover, 3) Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. (Lafay-Cousin L, et al. Cancers (Basel). 2022 Feb 7;14(3):837.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACNS0334 Arm B Includes Induction Plus Consolidation Chemotherapy, Autologous PBSC","conceptCode":"C203575","definition":"Patients randomized with the following course sequence: 1) Induction: Patients receive vincristine sulfate intravenously (IV)  on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or orally every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses, 2) Consolidation Chemotherapy: Patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover, 3) Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. (Lafay-Cousin L, et al. Cancers (Basel). 2022 Feb 7;14(3):837.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76CE-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E2-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"EE99 Not Randomized","valueDescription":null,"ValueMeaning":{"publicId":"14679015","version":"1","preferredName":"EE99 Not Randomized","longName":"14679015v1.00","preferredDefinition":"Patients are not randomized for treatment. (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EE99 Not Randomized","conceptCode":"C203576","definition":"Patients are not randomized for treatment. (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76CF-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E3-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"EE99 R1-VAC","valueDescription":null,"ValueMeaning":{"publicId":"14679016","version":"1","preferredName":"EE99 R1-VAC","longName":"14679016v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Group 1: Vincristine, dactinomycin and cyclophosphamide (VAC) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EE99 R1-VAC","conceptCode":"C203577","definition":"Patients randomized with the following course sequence: 1) Group 1: Vincristine, dactinomycin and cyclophosphamide (VAC) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76D0-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E4-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"EE99 R1-VAI","valueDescription":null,"ValueMeaning":{"publicId":"14679017","version":"1","preferredName":"EE99 R1-VAI","longName":"14679017v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Group 1: Vincristine, dactinomycin, ifosfamide (VAI) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EE99 R1-VAI","conceptCode":"C203578","definition":"Patients randomized with the following course sequence: 1) Group 1: Vincristine, dactinomycin, ifosfamide (VAI) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76D1-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E5-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"EE99 R2Loc-BuMel","valueDescription":null,"ValueMeaning":{"publicId":"14679018","version":"1","preferredName":"EE99 R2Loc-BuMel","longName":"14679018v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Group 2 localized disease: High-dose busulfan and melphalan (Bu-Mel) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EE99 R2Loc-BuMel","conceptCode":"C203579","definition":"Patients randomized with the following course sequence: 1) Group 2 localized disease: High-dose busulfan and melphalan (Bu-Mel) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76D2-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E6-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"EE99 R2Loc-VAI","valueDescription":null,"ValueMeaning":{"publicId":"14679019","version":"1","preferredName":"EE99 R2Loc-VAI","longName":"14679019v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Group 2 localized disease: Vincristine, dactinomycin, ifosfamide (VAI) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EE99 R2Loc-VAI","conceptCode":"C203580","definition":"Patients randomized with the following course sequence: 1) Group 2 localized disease: Vincristine, dactinomycin, ifosfamide (VAI) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76D3-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E7-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"EE99 R2Pulm-BuMel","valueDescription":null,"ValueMeaning":{"publicId":"14679020","version":"1","preferredName":"EE99 R2Pulm-BuMel","longName":"14679020v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Group 2 pulmonary metastases disease: High-dose busulfan and melphalan (Bu-Mel) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EE99 R2Pulm-BuMel","conceptCode":"C203581","definition":"Patients randomized with the following course sequence: 1) Group 2 pulmonary metastases disease: High-dose busulfan and melphalan (Bu-Mel) (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76D4-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E8-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"EE99 R2Pulm-VAI Plus Lung RT","valueDescription":null,"ValueMeaning":{"publicId":"14679021","version":"1","preferredName":"EE99 R2Pulm-VAI Plus Lung RT","longName":"14679021v1.00","preferredDefinition":"Patients randomized with the following course sequence: 1) Group 2 pulmonary metastases disease: Vincristine, dactinomycin, ifosfamide (VAI), 2) Whole lung radiotherapy (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EE99 R2Pulm-VAI Plus Lung RT","conceptCode":"C203582","definition":"Patients randomized with the following course sequence: 1) Group 2 pulmonary metastases disease: Vincristine, dactinomycin, ifosfamide (VAI), 2) Whole lung radiotherapy (Dirksen U, et al. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. Le Deley MC, et al. J Clin Oncol. 2014 Aug 10;32(23):2440-8.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F1120C8-76D5-5A71-E063-731AD00A8325","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F1120C8-76E9-5A71-E063-731AD00A8325","beginDate":"2024-01-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2024-01-16","modifiedBy":"SOKKERL","dateModified":"2024-01-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12988908","version":"1","preferredName":"Protocol Treatment Arm Identifier","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"12988908v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6453C2B-51E6-39A8-E053-731AD00AE8CE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-03-06","modifiedBy":"COLBERTM","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Incomplete","id":"F6453C2B-51E7-39A8-E053-731AD00AE8CE","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-03-06","modifiedBy":"SOKKERL","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":"1/8/24 RS changed to Incomplete while waiting for PCDC to provide citations for 22 new PVs that need concepts. mr; \r\n3/6/23 Created per PCDC metadata template. mr","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"12173174","version":"1","longName":"PCDC Aggregated Dictionary","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"12173175","version":"1","longName":"Protocol","context":"Pediatric Cancer"},{"publicId":"12173182","version":"1","longName":"Subject Characteristics","context":"Pediatric Cancer"}]},{"publicId":"13574489","version":"1","longName":"Childhood Cancer Data Initiative","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"13574490","version":"1","longName":"Study","context":"Pediatric Cancer"},{"publicId":"13596247","version":"1","longName":"Study Arm","context":"Pediatric Cancer"}]},{"publicId":"13954630","version":"1","longName":"All Pediatric Core CDEs","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"14599255","version":"1","longName":"Administrative","context":"Pediatric Cancer"}]}],"AlternateNames":[{"name":"TREATMENT_ARM","type":"PCDC Alt Name","context":"Pediatric Cancer"},{"name":"Treatment Arm","type":"Ped Cancer Alt Name","context":"Pediatric Cancer"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Treatment Arm","url":null,"context":"Pediatric Cancer"}],"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"F6454675-7650-3A9E-E053-731AD00A4415","latestVersionIndicator":"Yes","beginDate":"2023-03-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-03-06","modifiedBy":"COLBERTM","dateModified":"2024-01-25","changeDescription":null,"administrativeNotes":"1/25/24 22 new PVs added on 1/16 by LS. PCDC provided citations and EVS created the concepts. mr; \r\n1/8/24 RS on VD changed to Incomplete while waiting for PCDC to provide citations for 22 new PVs that need concepts. mr; \r\n1/5/24 removed CCDI alt name and \"protocol\" from LN for consistency with CCDI variable. jk; 3/6/23 Created per PCDC metadata template. mr","unresolvedIssues":null,"deletedIndicator":"No"}}